Mergers & Acquisitions ·
Catalyst Pharmaceuticals, Inc. completed its merger with Angelini Pharma S.p.A. on July 15, 2026, becoming a wholly…
CPRXCatalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. completed its merger with Angelini Pharma S.p.A. on July 15, 2026, becoming a wholly owned subsidiary of Parent. Each outstanding share of common stock was canceled and converted into the right to receive $31.50 per share in cash. The company's common stock will be suspended from trading on Nasdaq. Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and treatment of rare neuromuscular diseases.